Table III.

Post-treatment changes of indexes between two groups (x ± s)

Parameter	Change in values
	Etoricoxib group(n = 53)	Colchicine group(n = 52)	t value	P-value	Etoricoxib group(n = 53)	Colchicine group(n = 52)	t value	P-value
5 days after treatment:
White blood cells [× 109/l]	6.78 ±1.01	6.65 ±1.19	0.566	0.573	–1.99 ±1.04	–2.30 ±1.24	1.364	0.176
Joint pain scores	2.25 ±1.07	2.15 ±1.24	0.404	0.687	–4.26 ±1.50	–4.56 ±1.47	1.013	0.314
Joint swelling scores	0.77 ±0.57	0.73 ±0.64	0.213	0.832	–0.90 ±0.66	–1.03 ±0.72	0.748	0.458
Limitation of joint activity scores	0.77 ±0.50	0.70 ±0.60	0.468	0.642	–1.03 ±0.67	–1.17 ±0.65	0.784	0.436
IL-1β [pg/ml]	33.2 ±15.3	29.6 ±15.9†	1.154	0.251	–2.7 ±7.2	–8.7 ±8.4†	3.905	< 0.001
COX-2 [pg/ml]	16.1 ±8.2	20.3 ±8.8*	–2.576	0.011	–4.7 ±4.1	–0.7 ±3.9†	–5.003	< 0.001
miR223-3p	2.62 ±1.18	2.88 ±1.37	–1.045	0.298	0.15 ±0.40	0.67 ±0.78†	–4.282	< 0.001
miR451a	0.95 ±0.43	0.79 ±0.41	1.948	0.054	0.17 ±0.10	0.05 ±0.07†	8.035	< 0.001
10 days after treatment:
ALT [U/l]	31.7 ±9.3	35.1 ±11.4	–1.663	0.099	1.2 ±7.7	5.1 ±8.1*	–2.521	0.013
AST [U/l]	27.0 ±8.9	28.4 ±9.6	–0.810	0.420	1.1 ±5.6	2.5 ±6.8	–1.176	0.242
Serum creatinine [μmol/l]	61.3 ±11.2	61.6 ±11.1	–0.135	0.893	0.4 ±8.0	2.1 ±5.2	–1.283	0.202
Serum uric acid [μmol/l]	499 ±66	496 ±70	0.246	0.806	–5 ±9	–2 ±18	–1.167	0.246
Joint pain scores	1.02 ±0.84	0.96 ±0.91	0.336	0.738	–5.49 ±1.51	–5.75 ±1.57	0.862	0.351
IL-1β [pg/ml]	25.7 ±10.9	17.1 ±8.1	4.578	< 0.001	–10.2 ±7.1	–21.2 ±10.9	6.115	< 0.001
COX-2 [pg/ml]	10.6 ±4.6	14.1 ±4.9†	–3.771	< 0.001	–10.1 ±7.5	–7.0 ±5.9*	–2.388	0.019
miR223-3p	3.23 ±1.48	4.56 ±1.80†	–4.145	< 0.001	0.77 ±0.89	2.35 ±1.08†	–8.227	< 0.001
miR451a	1.67 ±0.66	1.12 ±0.54†	4.713	< 0.001	0.90 ±0.36	0.37 ±0.19†	9.225	< 0.001

^†p < 0.01 vs. etoricoxib group;

^*p < 0.05 vs. etoricoxib group.